Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Shares Outstanding (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Shares Outstanding data on record, last reported at $45.7 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 13.35% year-over-year to $45.7 million; the TTM value through Sep 2025 reached $45.7 million, up 13.35%, while the annual FY2024 figure was $45.6 million, 46.34% up from the prior year.
  • Shares Outstanding reached $45.7 million in Q3 2025 per CAPR's latest filing, roughly flat from $45.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $45.7 million in Q3 2025 and bottomed at $22.8 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $30.9 million, with a median of $25.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 148.11% in 2021, then grew 2.29% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $24.2 million in 2021, then increased by 4.37% to $25.2 million in 2022, then rose by 23.4% to $31.1 million in 2023, then surged by 46.34% to $45.6 million in 2024, then rose by 0.3% to $45.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $45.7 million in Q3 2025, $45.7 million in Q2 2025, and $45.7 million in Q1 2025.